Gardasil as three dose regimen — Competitive Intelligence Brief

Gardasil as three dose regimen (Gardasil as three dose regimen) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant quadrivalent HPV vaccine. Area: Oncology / Infectious Disease / Immunology.

phase 3 Recombinant quadrivalent HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18 L1 capsid protein Oncology / Infectious Disease / Immunology Biologic

Target snapshot

Gardasil as three dose regimen (Gardasil as three dose regimen) — Serum Institute of India Pvt. Ltd.. Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gardasil as three dose regimen TARGET	Gardasil as three dose regimen	Serum Institute of India Pvt. Ltd.	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18 L1 capsid protein
Vaccination with Gardasil	Vaccination with Gardasil	Assistance Publique - Hôpitaux de Paris	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18
Comparator: Gardasil	Comparator: Gardasil	Merck Sharp & Dohme LLC	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant quadrivalent HPV vaccine class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Merck Sharp & Dohme LLC · 1 drug in this class
3. Serum Institute of India Pvt. Ltd. · 1 drug in this class